Methods and compositions for sleep disorders and other disorders

Patent metadata

Field	Value
Publication number	US-9616061-B2
Application number	US-201514885813-A
Country	US
Kind code	B2
Filing date	Oct 16, 2015
Priority date	May 27, 2008
Publication date	Apr 11, 2017
Grant date	Apr 11, 2017

Abstract

Use of particular substituted heterocycle fused gamma-carboline compounds as pharmaceuticals and pharmaceutical compositions comprising them for the treatment of one or more disorders involving the 5-HT2A, SERT and/or dopamine D2 pathways are disclosed. In addition, the compounds may be combined with other therapeutic agents for the treatment of one or more sleep disorders, depression, psychosis, dyskinesias, and/or Parkinson's disease or any combinations.

First claim

The invention claimed is:

1. A pharmaceutical composition in oral unit dose form comprising an amount of from 0.1-20 mg of a Compound of Formula I:

wherein X is —N(CH 3 ); and Y is —C(O)—, in free or pharmaceutically acceptable salt form, in combination or association with a pharmaceutically acceptable diluent or carrier, provided that in the case of a salt, the weight is calculated as the free base.

2. The pharmaceutical composition according to claim 1 wherein the oral unit dose form is a tablet.

3. The pharmaceutical composition according to claim 1 wherein the oral unit dose form is a capsule.

4. The pharmaceutical composition according to claim 1 wherein the amount of Compound of Formula I is 0.5-10 mg.

5. The pharmaceutical composition according to claim 1 wherein the amount of Compound of Formula I is 2.5 mg.

6. The pharmaceutical composition according to claim 1 wherein the Compound of Formula I is in the form of the tosylate salt.

7. The pharmaceutical composition according to claim 6 , wherein the amount of Compound of Formula I is 0.5-10 mg.

8. The pharmaceutical composition according to claim 6 wherein the amount of Compound of Formula I is 2.5 mg.

9. The pharmaceutical composition according to claim 6 wherein the amount of Compound of Formula I is 3 mg.

10. The pharmaceutical composition according to claim 6 wherein the amount of Compound of Formula I is 4 mg.

11. The pharmaceutical composition according to claim 6 wherein the amount of Compound of Formula I is 5 mg.

12. The pharmaceutical composition according to claim 6 wherein the amount of Compound of Formula I is 10 mg.

13. The pharmaceutical composition according to claim 6 wherein the amount of Compound of Formula I is 20 mg.

14. A pharmaceutical composition comprising an amount of from 2.5-50 mg the Compound of Formula:

in free or pharmaceutically acceptable salt form.

15. The pharmaceutical composition according to claim 14 wherein the Compound of Formula I is in the form of the tosylate salt.

16. The pharmaceutical composition according to claim 15 , wherein the amount of Compound of Formula I is from 1-10 mg.

17. The pharmaceutical composition according to claim 15 , wherein the amount of Compound of Formula I is from 10-30 mg.

18. The pharmaceutical composition according to claim 15 wherein the amount of Compound of Formula I is 2.5 mg.

19. The pharmaceutical composition according to claim 15 wherein the amount of Compound of Formula I is 5 mg.

20. The pharmaceutical composition according to claim 15 wherein the composition is an oral unit dose form in the form of a tablet.

21. The pharmaceutical composition according to claim 15 wherein the composition is an oral unit dose form in the form of a capsule.

22. The pharmaceutical composition according to claim 1 , further comprising one or more therapeutic agents selected from the group consisting of compounds that modulate GABA activity, a GABAB agonist, a 5-HT modulator, a melatonin agonist, an ion channel modulator, a serotonin-2 antagonist/reuptake inhibitor (SARIs), an orexin receptor antagonist, an H3 agonist, a noradrenergic antagonist, a galanin agonist, a CRH antagonist, human growth hormone, a growth hormone agonist, estrogen, an estrogen agonist, a neurokinin-I drug, an anti-depressant, and an antipsychotic agent, in free or pharmaceutically acceptable salt form.

23. The pharmaceutical composition according to claim 1 , further comprising one or more therapeutic agents selected from the group consisting of modafinil, armodafinil, doxepin, alprazolam, bromazepam, clobazam, clonazepam, clorazepate, diazepam, flunitrazepam, flurazepam, lorazepam, midazolam, nitrazepam, oxazepam, temazapam, triazolam, indiplon, zopiclone, eszopiclone, zaleplon, Zolpidem, gabaxadol, vigabatrin, tiagabine, EVT 201, estazolam, ketanserin, risperidone, eplivanserin, volinanserin, pruvanserin, MDL 100907, HY10275, APD125, AVE8488, repinotan, sarizotan, eptapirone, buspirone, MN-305, melatonin, ramelteon, VEC-162, PD-6735, agomelatine, lamotrigine, gabapentin, pregabalin, orexin, a 1,3-biarylurea, SB-334867-a, GW649868, a benzamide derivative, Org 50081, ritanserin, nefazodone, serzone, trazodone, Casopitant, amitriptyline, amoxapine, bupropion, citalopram, clomipramine, desipramine, doxepin, duloxetine, escitaloprame, fluoxetine, fluvoxamine, imipramine, isocarboxazid, maprotiline, mirtazapine, nefazodone, nortriptyline, paroxetine, phenlzine sulfate, protiptyline, sertraline, tranylcypromine, trazodone, trimipramine, velafaxine, chlorpromazine, haloperidol, droperidol, fluphenazine, loxapine, mesoridazine molidone, perphenazine, pimozide, prochlorperazine promazine, thioridazine, thiothixene, trifluoperazine, clozapine, aripiparazole, olanzapine, quetiapine, risperidone, ziprasidone and paliperidone, in free or pharmaceutically acceptable salt form.

24. The pharmaceutical composition according to claim 1 , further comprising one or more therapeutic agents selected from the group consisting of L-dopa, co-careldopa, duodopa, stalova, symmetrel, benzotropine, biperiden, bromocryiptine, entacapone, pergolide, pramipexole, procyclidine, ropinirole, selegiline and tolcapone.

25. The pharmaceutical composition according to claim 23 wherein the amount of Compound of Formula I is 2.5 mg.

26. The pharmaceutical composition according to claim 23 wherein the amount of Compound of Formula I is 5 mg.

27. The pharmaceutical composition according to claim 24 wherein the amount of Compound of Formula I is 2.5 mg.

28. The pharmaceutical composition according to claim 24 wherein the amount of Compound of Formula I is 5 mg.

29. The pharmaceutical composition according to claim 1 wherein the amount of Compound of Formula I is 5 mg.

Assignees

• Intra Cellular Therapies Inc

Inventors

• Mates Sharon
• Fienberg Allen
• Wennogle Lawrence

Classifications

• A61P5/06

  of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH · CPC title

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61K31/437 Primary

  the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline · CPC title

• A61P25/20

  Hypnotics; Sedatives · CPC title

• A61K45/06

  Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title